NEWS
2020.10.1
Rebirthel concluded the research license agreement with Otsuka Pharmaceutical.
Rebirthel concluded the research license agreement with Otsuka Pharmaceutical on October 1st, 2020. Under this agreement, Rebirthel will provide its patented technology to Otsuka Pharmaceutical, and Otsuka Pharmaceutical will utilize this technology for the development of the cancer immunotherapy using allogeneic T cells. For details, please refer to the attached press release.